Patient Prostate Cancer Guidelines Available
NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.
NEW YORK--The National Comprehensive Cancer Network (NCCN) and the American Cancer Society (ACS) have collaborated to translate the NCCN prostate cancer guidelines into a patient-friendly resource for appropriate treatment, the two organizations announced at a press briefing.
Incorporating the clinical experience of the 17 NCCN member institutions, these guidelines offer prostate cancer patients and their families the reliable, specific, and easy-to-understand information they need to make treatment decisions.
In March, the NCCN and ACS released breast cancer guidelines for patients, resulting in 1.5 million visits to the NCCN website.The prostate cancer guidelines are available on the NCCN website (www.nccn.org),and the ACS website (www.cancer.org).
The prostate cancer treatment guidelines for patients will also be published in the August/September 1999 issue of InTouch, PRR, Inc.s cancer magazine for consumers.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
